Hirsutine ameliorates hepatic and cardiac insulin resistance in high-fat diet-induced diabetic mice and in vitro models
Authors:
Open Access
- 1 March 2022
- journal article
- research article
- Published by Elsevier in Pharmacological Research
- Vol. 177, 105917
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (81973320)
- National Natural Science Foundation of China (AD20238024)
- Shanghai Municipal Education Commission (ZDSYS14005)
This publication has 58 references indexed in Scilit:
- Hepatic glucose sensing is required to preserve β cell glucose competenceJournal of Clinical Investigation, 2013
- AMPK: a nutrient and energy sensor that maintains energy homeostasisNature Reviews Molecular Cell Biology, 2012
- Metabolic stress–induced activation of FoxO1 triggers diabetic cardiomyopathy in miceJournal of Clinical Investigation, 2012
- Hepatic Sirt1 deficiency in mice impairs mTorc2/Akt signaling and results in hyperglycemia, oxidative damage, and insulin resistanceJournal of Clinical Investigation, 2011
- Protective effects of novel single compound, Hirsutine on hypoxic neonatal rat cardiomyocytesEuropean Journal of Pharmacology, 2011
- AMPK: An Emerging Drug Target for Diabetes and the Metabolic SyndromeCell Metabolism, 2009
- Insulin resistance, inflammation, and non-alcoholic fatty liver diseaseTrends in Endocrinology & Metabolism, 2008
- AMP-Activated Protein Kinase Regulates GLUT4 Transcription by Phosphorylating Histone Deacetylase 5Diabetes, 2008
- SIRT1 Improves Insulin Sensitivity under Insulin-Resistant Conditions by Repressing PTP1BCell Metabolism, 2007
- AMP-activated protein kinase (AMPK) action in skeletal muscle via direct phosphorylation of PGC-1αProceedings of the National Academy of Sciences, 2007